Chronic Bronchitis
4,000,000+
People living with Chronic Bronchitis with Moderate/Severe Mucus Symptoms in the US
Limited Treatment Options
Lack efficacy, especially for mucus and cough
ARINA-1 is poised to be a first-line therapy for improving airway hygiene by clearing mucus and decreasing inflammation in Chronic Bronchitis (CB).
CB is most commonly caused by chronic bronchial inflammation that leads to excess mucus in the airway and scarring. CB is characterized by excess mucus, chronic cough, and progressive lung damage that can lead to decreased pulmonary function. CB primarily impacts people over the age of 40 and significantly impairs quality of life. Current treatments vary in efficacy and have a limited impact on quality of life.
Current Status
Investigator Sponsored Clinical Trial
Safety and Efficacy of ARINA-1 in Chronic Bronchitis
Primary Endpoint:
Safety
Secondary Endpoints:
Quality of life, cough frequency, and the impact of ARINA-1 on mucus rheology and systemic inflammatory markers
Duration:
28 days on therapy; 28 days off therapy
Principle Investigator:
Charlie Strange, MD at the Medical University of South Carolina
Patient Enrollment Status
Other Target Indications for ARINA·1
